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Abstract: Impaired glucocorticoid (GC) signaling is a significant factor in aging, stress, and neu-
rodegenerative diseases such as Alzheimer’s disease. Therefore, the study of GC-mediated stress
responses to chronic moderately stressful situations, which occur in daily life, is of huge interest for
the design of pharmacological strategies toward the prevention of neurodegeneration. To address this
issue, SAMP8 mice were exposed to the chronic mild stress (CMS) paradigm for 4 weeks and treated
with RL-118, an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. The inhibition of
this enzyme is linked with a reduction in GC levels and cognitive improvement, while CMS exposure
has been associated with reduced cognitive performance. The aim of this project was to assess
whether RL-118 treatment could reverse the deleterious effects of CMS on cognition and behavioral
abilities and to evaluate the molecular mechanisms that compromise healthy aging in SAMP8 mice.
First, we confirmed the target engagement between RL-118 and 11β-HSD1. Additionally, we showed
that DNA methylation, hydroxymethylation, and histone phosphorylation were decreased by CMS
induction, and increased by RL-118 treatment. In addition, CMS exposure caused the accumulation
of reactive oxygen species (ROS)-induced damage and increased pro-oxidant enzymes—as well as
pro-inflammatory mediators—through the NF-κB pathway and astrogliosis markers, such as GFAP.
Of note, these modifications were reversed by 11β-HSD1 inhibition. Remarkably, although CMS
altered mTORC1 signaling, autophagy was increased in the SAMP8 RL-118-treated mice. We also
showed an increase in amyloidogenic processes and a decrease in synaptic plasticity and neuronal
remodeling markers in mice under CMS, which were consequently modified by RL-118 treatment.
In conclusion, 11β-HSD1 inhibition through RL-118 ameliorated the detrimental effects induced by
CMS, including epigenetic and cognitive disturbances, indicating that GC-excess attenuation shows
potential as a therapeutic strategy for age-related cognitive decline and AD.
Keywords: glucocorticoids; stress; target engagement; aging; epigenetics; oxidative stress; inflamma-
tion; neurodegeneration; cognition
1. Introduction
Stress is a key determinant of the healthy or pathological aging of the brain [1,2].
Stressful situations activate a neuroendocrine response, which leads to the release of
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catecholamines followed by glucocorticoids (GCs). Active GCs bind to their receptors,
promoting slow genomic actions as well as rapid nongenomic effects, such as glucose
release, lipolysis, motivation to eat palatable food, and up-regulation of the expression of
anti-inflammatory cytokines [3,4]. Its release is determined by the quality, intensity, and
chronicity of the stressful stimulus [5]. In the brain, stressful experiences are adaptive
and necessary for the establishment of enduring memories and to facilitate the restoration
of physiological and behavioral homeostasis. When stressful situations persist over a
long period of time, memory formation and reasoning become impaired [6,7]. In some
situations, however, the deleterious effects of stress and GCs in the brain can be transient,
since stress-induced hippocampal atrophy and hippocampal-dependent behavior may be
reversed after a stress-free period. However, a growing body of evidence suggests that
high GC exposure in early life can adversely program the release of GCs and increase
susceptibility to the development of metabolic, neuropsychiatric, and neurodegenerative
diseases [8], as well as induce changes in brain structure—including the generation and
loss of neurons and dendritic atrophy—and brain function, affecting electrophysiological
activity and cellular signaling [9,10].
Several studies indicate that environmental stressors influence hypothalamic–pituitary–
adrenal (HPA) axis activity and behavior by altering the methylation status of the key
genes concerned with the regulation of stress responses [2,8,11]. In line with this, recent
evidence has demonstrated significant associations between epigenetic alterations and
stress, showing that, under the influence of chronic stressors, histone acetylation and DNA
methylation are decreased, among other alterations [11,12]. Moreover, prolonged exposure
to GCs is associated with immunosuppression, metabolic syndrome, diabetes, osteoporo-
sis, reproductive failure, hypertension, and mood and affective disorders. Mal-adaptive
adjustments to stress may, sequentially, lead to symptoms of depression and Alzheimer’s
disease (AD). Additionally, recent clinical studies suggest that GCs are implicated in the
pathogenesis and/or progression of AD [9,13]. An increase in amyloid β (Aβ) deposits and
hyperphosphorylated tau have been associated with chronic stress [14,15]. Importantly,
stressful events can also have long-term consequences for the immune system. Nuclear
factor-κB (NF-κB) triggers a feed-forward cycle in which increased cytokine levels result
in resistance to GC-induced immunosuppression, leading to further increases in cytokine
release and consequent activation of the HPA axis [16,17]. Additionally, pro-inflammatory
cytokines have been implicated in the genesis of AD, as well as in the formation of amyloid
plaques and Aβ production. Interestingly, HPA axis activation has been linked to oxidative
stress (OS) and reactive oxygen species (ROS) production [13,18,19], which are other factors
involved in AD pathology and progression. Moreover, GCs are also involved in the regu-
lation of cell fate, by modulating pro-/anti-apoptotic mechanisms and survival proteins,
such as brain-derived neurotrophic factor (BDNF), inducible nitric oxide synthase (iNOS),
B-cell lymphoma 2 (Bcl2), and the neural cell adhesion molecule (NCAM), suggesting that
they exert significant influence over neuroplasticity [2,7,20,21]. It should be noted that the
activation of autophagy becomes crucial for cell survival and longevity, as this process
participates in the elimination of disrupted proteins and is implied in the maintenance of
cellular homeostasis [17].
The localization of active GCs is controlled by the 11β-hydroxysteroid dehydrogenase
type 1 (11β-HSD1) enzyme. Inhibition of this enzyme has been associated with neuropro-
tective effects [6,15]. In particular, we reported that RL-118, a specific 11β-HSD1 inhibitor,
prevented age-related cognitive decline in mice, even under metabolic stress [15,22,23].
The aim of this study was to confirm the target engagement of RL-118 to 11β-HSD1 and to
evaluate the effects of 11β-HSD1 inhibition during chronic stress exposure in a senescence
mice model (SAMP8).
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2. Results
2.1. RL-118 Demonstrates Target Engagement with 11β-HSD1 Enzyme in the TAPS Assay
The RL-118 target engagement was determined in the TAPS. The peak area of RL-118
quantified was relative to the number of cells and was found to be higher in cells expressing
the 11β-HSD1 enzyme (11β-HSD1-positive), compared to cells found to have no expression
of the enzyme following transfection (11β-HSD1-negative) (Figure 1). Additionally, the
peak area was significantly higher in 11β-HSD1-positive cells than in Crimson-positive
cells, indicating that the RL-118 drug is selective for 11β-HSD1.
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Figure 1. TAPS Assay results showing the peak area per cell. Values are the mean ± standard error
of the mean (SEM) (n = 3), *** p < 0.0001. ** p < 0.01 +/− x protein interaction; *** p < 0.001 +/− main
effect; **** p < 0.0001 protein main effect. The Y-axis represents the peak area obtained in LC-MS
divided by the number of cells evaluated after lysis (see methodology for details).
2.2. CMS-Modulated Epigenetic Marks Are Controlled by 11β-HSD1 Inhibition
Regarding DNA methylation, CMS reduced global DNA methylation and 5-hydroxy
methylation compared to the control group. 11β-HSD1 inhibition, meanwhile, increased
DNA methylation in both 11β-HSD1 inhibitor treated groups (Figure 2A,B). In accordance
with this, DNA-methyltransferase 1 (Dnmt ) and ten-eleven translocase 2 (Tet2) gene expres-
sions were lower in the CMS-treated groups and increased in the 11β-HSD1i-treated control
group (Figure 2C,D).
As far as histone epigenetic modifications are concerned, histone deacetylase 2 (Hdac2)
gene expression was significantly diminished by RL-118 treatment in both groups, while
CMS induced a slight increas compared to the c trol animals (Figure 2E). The mice
under CMS showed lower Lys12 cetylated histone 4 (H4K12) protein levels. In line with
previous results, H4K12 protein levels were higher in the mice in the 11β-HSD1i control
group (Figure 2F). Lys9 acetylated histone 3 (H3K9) and di-methylated H3K9 (H3K9me2)
protein levels were higher in the CMS group and reduced after 11β-HSD1 inhibition by
RL-118 (Figure 2G,H).
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Figure 2. Representative results from epigenetic marks. Global 5-methylated cytosine (A) and 5-
hydroxymethylated cytosine levels (B). Relative gene expression of Dnmt1 (C), Tet2 (D), and Hdac2 
(E). Representative Western blot for the ratio of Lys12 acetylated H4 protein levels and quantifica-
tion (F), the ratio of Lys9 acetylated H3 protein levels and quantification (G), and the ratio of
H3K9me2 protein levels and quantification (H). Gene expression levels were determined by real-
time PCR. Western blot values in bar graphs are adjusted to 100% for protein levels of SAMP8 Con-
trol (Control). Values are mean ± standard error of the mean (SEM) (n = 6 for each group). * p < 0.05; 
** p < 0.01; *** p < 0.001. 
H
Figure 2. Representative results from epigenetic marks. Global 5-methylated cytosine (A) and 5-
hydroxymethylated cyto ine levels (B). Relative gene expression of Dnmt1 (C), Tet2 (D), and Hdac2
(E). Representative Western blot for the ratio of Lys12 acetylated H4 protein levels and quantification
(F), the ratio of Lys9 acetylated H3 protein levels and quantification (G), and the ratio of H3K9me2
protein levels and quantification (H). Gene expression levels were determined by real-time PCR.
Western blot values in bar graphs are adjusted to 100% for protein levels of SAMP8 Control (Control).
Values are mean ± standard error of the mean (SEM) (n = 6 for each group). 11β-HSD1 and CMS
main effects as well as interactions were determined. * p < 0.05; ** p < 0.01; *** p < 0.001.
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2.3. OS Increase Induced by CMS Was Prevented by RL-118 Treatment
CMS intensified ROS concentrations in both CMS groups compared to the control
mice. However, RL-118 drug treatment contributed to a decrease in ROS levels (Figure 3A).
ROS accumulation is regulated by antioxidant and pro-oxidant enzymes controlled by
nuclear erythroid-related factor 2 (Nrf2), such as aldehyde oxidase 1 (Aox1). Hereby,
decreased Nrf2 protein levels were observed after 11β-HSD1 inhibition, but increased
levels were observed after CMS treatment (Figure 3B). In accordance, Aox1 gene expression
was significantly diminished by RL-118 in the group under CMS, but increased in the CMS
control group (Figure 3C). Indeed, the same gene expression pattern was observed for
iNOS, an enzyme involved in the synthesis of pro-oxidant molecules (Figure 3D).
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2.4. Pro-Inflammatory Markers Were Reduced after 11β-HSD1 Inhibition  
NF-κB is a protein complex that regulates cytokine production, inflammatory signal-
ing, and immune responses to infection. Although no statistical differences were observed 
in the NF-κB protein levels, the levels were decreased after RL-118 treatment in both 
treated groups (Figure 4A). However, there were changes in the gene expression of several 
cytokines controlled by this nuclear factor. CMS induced an increase in interleukin 1β (Il-
Figure 3. Representative results from pro-oxidant vs antioxidant mechanism imbalances. Represen-
tative ROS accumulation was measured by the hydrogen peroxide concentration in homogenates
of hippocampus tissue (A). Representative Western blot for the ratio of nuclear/cytoplasmic NRF2
protein levels and quantification (B). Relative gene expression of Aox1 (C) and iNOS (D). Western blot
values in bar graphs are adjusted to 100% for protein levels of SAMP8 Control (Control). Gene expres-
sion l vels were determined by real-time PCR. Values are mean ± stand d error of the mean (SEM)
(n = 6 for each group). 11β-HSD1 and CMS main effects as well as interactions were determined.
* p < 0.05; ** p < 0.01.
2.4. Pro-Inflammatory Markers Were Reduced after 11β-HSD1 Inhibition
NF-κB is a protein complex that regulates cytokine production, inflammatory signal-
ing, and immune responses to infection. Although no statistical differences were observed
in the NF-κB protein levels, the levels were decreased after RL-118 treatment in both treated
groups (Figure 4A). However, there were changes in the gene expression of several cy-
tokines controlled by this nuclear factor. CMS induced an increase in interleukin 1β (Il-1β),
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chemokine (C-X-C motif), ligand 2 (Cxcl-2), and tumor necrosis factor α (Tnf-α) gene expressions
in comparison to the control mice. By contrast, 11β-HSD1 inhibition significantly decreased
cytokine gene expression in the CMS-treated mice, while in the control mice, decreased
gene expression was only significant for Cxcl-2 (Figure 4B–D). Moreover, the evaluation of
glial fibrillar acidic protein (Gfap) gene expression demonstrated an increase due to CMS and
a decrease due to 11β-HSD1 inhibition (Figure 4E).
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chain 3B (LC3B). Beclin1 and LC3B are activators of the cellular cleaning process, while 
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Figure 4. Representative results from inflammatory pathways. Representative Western blot for NF-κB
protein levels and quantification (A). Relative gene expression of Il-1β (B), Cxcl2 (C), Tnf-α (D), and
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error of the mean (SEM) (n = 6 for each group). 11β-HSD1 and CMS main effects as well as interactions
were determined. * p < 0.05; ** p < 0.01.
2.5. 11β-HSD1 Inhibition Promoted CMS-Induced Autophagy
Several autophagy markers were eval ate i t is st y, including Beclin1, rapamycin-
sensitive TOR complex 1 (TORC1), and microtubule-associated protein 1A/1B light chain
3B (LC3B). Beclin1 and LC3B are activators of the cellular cleaning process, while TORC1 is
associated with autophagy inhibition. Mice under CMS showed higher p-TORC1 (Ser151)
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protein levels and an elevated LC3BI/LC3II ratio (Figure 5A–C). After 11β-HSD1 inhibitor
treatment, Beclin1 protein levels and the LC3BI/LC3II ratio were increased, both in the
control and CMS groups, while p-TORC1 (Ser151) levels were decreased.
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2.6. 11β-HSD1 Inhibition Rescued Mice from the Injurious Effects of CMS on APP Processing 
As shown herein, disintegrin and metalloproteinase domain protein 10 (Adam10) gene ex-
pression was decreased in the CMS group and subsequently recovered by RL-118 treat-
ment (Figure 6A). Furthermore, β-secretase 1 (Bace1) gene expression was decreased in both 
RL-118 treated groups and slightly increased after CMS exposure (Figure 6B). In line with 
these results, Aβ-precursor gene expression was increased in the CMS group and reversed 
by 11β-HSD1 inhibition (Figure 6C). Finally, the β-amyloid degradation process was as-
sessed by Neprilisin12 gene expression. It was found that RL-118 treatment consequently 
increased Neprilisin12 gene expression, which was decreased by CMS exposure (Figure 
6D).  
Figure 5. Representative results from the evaluation of the autophagy process. Representative
Western blot for Beclin1 protein levels and quantification (A), p-TORC1 (Ser 151) protein levels and
quantification (B), and the ratio of LC3 protein levels and quantification (C). Values in bar graphs are
adjusted to 100% for protein levels of SAMP8 Control (Control). Values are mean ± standard error of
the mean (SEM) (n = 4 for each group). 11β-HSD1 and CMS main effects as well as interactions were
determined. * p < 0.05; ** p < 0.01.
2.6. 11β-HSD1 Inhibition Rescued Mice from the Injurious Effects of CMS on APP Processing
As shown herein, disintegrin and metalloproteinase domain protein 10 (Adam10) gene
expression was decreased in the CMS group and subsequently recovered by RL-118 treat-
ment (Figure 6A). Furthermore, β-secretase 1 (Bace1) gene expression was decreased in both
RL-118 treated groups and slightly increased after CMS exposure (Figure 6B). In line with
these results, Aβ-precursor gene expression as increased in the CMS group and reversed by
11β-HSD1 inhibition (Figure 6C). Finally, the β-amyloid degradation process was assessed
by Neprilisin12 ge e expression. It was found that RL-118 treatment consequently increased
Neprilisin12 gene expression, which was decreased by CMS exposure (Figure 6D).
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2.7. 11β-HSD1 Inhibition by RL-118 Changed Synaptic Plasticity Markers after CMS
RL-118 increased cAMP r sponse element-bi din (Creb) gene expression, although this
change was not significant in the CMS group. By contrast, the ratio of pCREB/CREB was
reduced after CMS exposure but unmodified after RL-118 treatment (Figure 7A,B). Never-
theless, synaptic markers like postsynaptic density protein 95 (PSD95) and synaptophysin
protein levels were increased after 11β-HSD1 inhibition treatment, both in the control and
CMS groups (Figure 7C,D).





Figure 7. Representative results from neuroplasticity modulators. Relative gene expression of Creb 
(A). Representative Western blot for the ratio of p-CREB protein levels and quantification (B), PSD95 
protein levels and quantification (C), and synaptophysin protein levels and quantification (D). Gene 
expression levels were determined by real-time PCR. Western blot values in bar graphs are adjusted 
to 100% for protein levels of SAMP8 Control (Control). Values are mean ± standard error of the 
mean (SEM) (n = 6 for each group). * p < 0.05; ** p < 0.01; **** p < 0.0001. 
2.8. 11β-HSD1 Inhibition Increased Memory and Learning Abilities  
We assessed recognition and spatial memory, as well as learning ability, through the 
evaluation of NORT and MWM. CMS did not induce significant changes in the NORT DI 
values for short-term memory in comparison to the control mice, although recognition 
memory was impaired by CMS after 24 h of familiarization (Figure 8A,B). However, 11β-
HSD1-inhibitor treatment increased both short- and long-term recognition memory as the 
NORT DI was higher in RL-118 treated groups. On the other hand, the MWM learning 
curve demonstrates that all the mice learned where the platform was during the training 
days, as the latency to the platform was lower than the first day, although some groups 
performed better than others (Figure 8C). However, female mice under CMS and RL-118 
treatment showed better learning ability in comparison to the CMS group, demonstrated 
by the higher learning curve slope in those groups. Regarding performance on the MWM 
test day, CMS treatment did not have a significant effect on the evaluated parameters, 
although a trend towards the impairment of performance was observed. By contrast, RL-
118 treatment led to a subtle positive impact on mouse behavior, both in the control and 
CMS groups, since the distance traveled to reach the platform was reduced and was, sta-
tistically, significantly different in the control groups (Figure 8D). In line with these re-
sults, 11β-HSD1 inhibition was observed to increase target crossings as well as the time 
Figure 7. Representative results from neuroplasticity modulators. Relative gene expression of Creb
(A). Representative Western blot for the ratio of p-CREB protein levels and quantification (B), PSD95
rotein levels and quantific tion ( ), and synaptophysin protein levels and quantification (D). Gene
expression levels were determined by real-time PCR. Western blot values in bar graphs are adjusted
to 100% for protein levels of SAMP8 Control (Control). Values are mean ± standard error of the
mean (SEM) (n = 6 for each group). 11β-HSD1 and CMS main effects as well as interactions were
determined. * p < 0.05; ** p < 0.01; **** p < 0.0001.
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2.8. 11β-HSD1 Inhibition Increased Memory and Learning Abilities
We assessed recognition and spatial memory, as well as learning ability, through the
evaluation of NORT and MWM. CMS did not induce significant changes in the NORT DI
values for short-term memory in comparison to the control mice, although recognition
memory was impaired by CMS after 24 h of familiarization (Figure 8A,B). However, 11β-
HSD1-inhibitor treatment increased both short- and long-term recognition memory as the
NORT DI was higher in RL-118 treated groups. On the other hand, the MWM learning
curve demonstrates that all the mice learned where the platform was during the training
days, as the latency to the platform was lower than the first day, although some groups
performed better than others (Figure 8C). However, female mice under CMS and RL-118
treatment showed better learning ability in comparison to the CMS group, demonstrated
by the higher learning curve slope in those groups. Regarding performance on the MWM
test day, CMS treatment did not have a significant effect on the evaluated parameters,
although a trend towards the impairment of performance was observed. By contrast,
RL-118 treatment led to a subtle positive impact on mouse behavior, both in the control
and CMS groups, since the distance traveled to reach the platform was reduced and was,
statistically, significantly different in the control groups (Figure 8D). In line with these
results, 11β-HSD1 inhibition was observed to increase target crossings as well as the time
spent in the platform zone in both treated groups, compared to their littermates in the
control group (Figure 8E,F).
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3. Discussion
Impaired glucocorticoid (GC) signaling is a significant factor in aging, stress, and
neurodegenerative diseases, such as Alzheimer’s disease. Therefore, the study of GC-
mediated stress responses to chronic moderately stressful situations, which occur in daily
life, is of huge interest for the design of pharmacological strategies toward the prevention
of neurodegeneration.
Strong evidence demonstrating an association between prolonged exposure to GC
excess and diminished cognitive abilities has been reported [4]. Detrimental effects induced
by GCs may be the result of alterations in hippocampal electrophysiology, structure,
and function, as well as the deleterious effects on neurotransmission, metabolism, and
cell division and death. GC secretion responds to feed-forward signaling involving the
hypothalamic–pituitary–adrenal (HPA) axis, forming the stress response. Stressful stimuli
increase GC secretion and release to provide the energy necessary to cope with the stress.
Mounting evidence reports that chronic stress might lead to deleterious effects on the brain,
while acute stress may enhance memory [4,24]. Accordingly, it has been demonstrated
that the CMS paradigm reduces cognitive abilities and increases anxiety-like behavior in
mice [7,12].
Previously, we reported that RL-118, an 11β-HSD1 inhibitor, regulates the disposal
of active GCs [21,22]. Importantly, 11β-HSD1 inhibition enhanced cognitive abilities and
reduced AD hallmarks [15,23,25]. In accordance with these results, it has been described
that 11β-HSD1 expression in a mouse’s hippocampus and parietal cortex increases with
aging, and that overexpression accelerates age-related cognitive decline [26]. By contrast,
11β-HSD1 knockout mice resist age-dependent cognitive loss [27,28]. Moreover, we demon-
strated that RL-118 treatment promoted autophagy flux, as well as ER stress activation, to
reverse the deleterious effects exerted by prolonged exposure to GCs [15,22,23]. Overall, it
is suggested that 11β-HSD1 could be a feasible target for fighting against cognitive decline
in age-related pathologies. In fact, early clinical studies demonstrate that the 11β-HSD1
inhibitor (UE2343), currently in clinical phase II, is well-tolerated in AD patients [29].
Furthermore, many selective 11β-HSD1 inhibitors have reached clinical trials for metabolic
diseases, for example, AZD8329 and BVT.2733 [15].
To demonstrate that RL-118 specifically binds to the 11β-HSD1 enzyme, the target
engagement of RL-118 and 11β-HSD1 was determined using a novel methodology con-
sisting of FACS (fluorescence-activated cell sorting) coupled with mass spectrometry (MS)
analysis [30]. This assay of target engagement showed that RL-118 binds to its target in a
selective manner since it did not bind to other proteins. Therefore, we determined that the
molecular and behavioral effects observed after RL-118 administration to mice [15,22,23]
were the result of binding to the 11β-HSD1 enzyme.
The stress response may have a genetic and epigenetic origin, reflected in the efficiency
of the GC receptor (GR)-mediated GC negative feedback in the brain and/or the pituitary
gland that causes HPA axis hyperactivity [2,11,31]. To address whether and which changes
produced the chronic presence of stressors, we decided to evaluate two main epigenetic
marks: DNA methylation and histone acetylation. The former is implicated in controlling
neuronal gene expression and neural development. Dysregulation of this process is linked
to a wide range of neuronal disorders, including AD onset and progression. However, the
relationship between AD and altered 5-mC levels is not known [12,32]. The TET family
of enzymes can further oxidize 5-mC to 5-hmC. Generally, 5-mC is associated with gene
silencing and 5-hmC with the up-regulation of gene expressions [32,33]. According to
Puigoriol-Illamola et al. [12], CMS reduces those epigenetic marks, whereas treatment
with RL-118 restores the DNA methylation pattern after the detrimental stimulus. Of note,
reducing GC levels by inhibiting 11β-HSD1 also increased DNA hydroxymethylation in
the non-stressed mice that were treated. Likewise, the gene expressions for the enzymes
responsible for these processes, Dnmt1 and Tet2, were increased in both groups treated with
the 11β-HSD1 inhibitor, but decreased in the CMS group, suggesting a neuroprotective
effect [32–34]. Overall, the results suggest that further evaluation of gene-promoter-specific
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methylation is required to elucidate the precise epigenetic mechanisms and explain the
neuroprotective effects of RL-118 that were observed in the performed cognitive tests.
DNA methylation and histone modifications must act coordinately [34]. Generally,
histone acetylation is related to gene transcription by removing histone-positive charges
and thereby transforming condensed chromatin (heterochromatin) into a relaxed structure
(euchromatin) [35,36]. The 11β-HSD1-inhibitor treatment altered Hdac2 gene expression,
promoting a reduction in the control and CMS groups. In line with this, acetylated H4
showed higher protein levels in the RL-118-treated group, but not in the mice under
CMS. In accordance with Puigoriol-Illamola et al. [12], the SAMP8 mice under CMS
treatment showed higher H3K9 protein levels compared to the control group, which
were decreased after RL-118 treatment. The same profile was observed in H3K9me2
protein levels, suggesting that despite the increase in histone acetylation, the increased
methylation resulted in transcriptional repression or a more compacted chromatin state
in the CMS groups compared to the control mice. Furthermore, although RL-118 is not a
direct epigenetic-modulating drug, the reduction in GC production modified the epigenetic
landscape, confirming the importance of GC-regulating epigenetics.
It is well-established that a stressful environment affects oxidative balance [12,37,38].
In normal conditions, pro-oxidant molecules and antioxidant defense mechanisms are
balanced. However, in the presence of chronic stressors, as well as in aging and several
disorders, there is a decrease in the capacity of antioxidant enzymes, allowing ROS accumu-
lation. This eventually causes cellular damage and, finally, dysfunction of the system [39].
In accordance with this, the present work showed that the SAMP8 mice under CMS had an
increased ROS accumulation which was prevented in the animals treated with RL-118. OS
is frequently implicated as a potential factor in the progression of AD, though whether it is
a cause or consequence of the pathology is still undetermined [18]. Among antioxidant
defense mechanisms, the NRF2 pathway has been determined as a key indicator and
modulator of OS in neurodegeneration [39–41], because it regulates the gene expression of
different antioxidant enzymes. While NRF2 protects against oxidative and electrophilic
tissue injury, persistent activation of NRF2 signaling may also contribute to disease patho-
physiology [42]. Interestingly, NRF2 protein levels were decreased after RL-118 treatment,
suggesting that the attenuation of GC levels induces lower oxidative damage, while CMS
has the opposite effect. Accordingly, Aox1 gene expression was reduced after RL-118
treatment in the CMS group. Likewise, other OS modulators that were evaluated, such as
iNOS, showed an increase in the CMS group compared to the control group and displayed
decreased gene expression after RL-118 treatment. Moreover, iNOS gene expression has
been reported to be regulated by inflammatory signaling, particularly through NF-κB [43].
Overall, results indicate that a stressful environment increases pro-oxidant mechanisms
and suggest that 11β-HSD1 inhibition promotes antioxidant defenses to cope with OS in a
mouse model of aging, even under CMS conditions.
Regarding neuroinflammation, NF-κB has a pivotal role in inflammatory responses
since it induces the expression of various pro-inflammatory genes, including those en-
coding cytokines and chemokines, and participates in inflammasome regulation [44,45].
It triggers a feed-forward cycle which increases cytokine production. This, in turn, re-
sults in resistance to GC-induced immunosuppression, leading to further increases in
cytokine release and, therefore, the activation of the HPA axis [16,17]. While this result
was not statistically significant, 11β-HSD1 inhibition tended to reduce NF-κB protein
levels. Accordingly, we found decreased pro-inflammatory cytokine (IL1β, Cxcl2, and
TNFα) gene expressions—which were increased due to CMS—after 11β-HSD1-inhibitor
treatment. Moreover, Il-10 and Il-6 gene expression results reinforce this finding (data
not shown). Such pro-inflammatory cytokines are known to activate the HPA axis and
potentiate GC resistance [2] and have been implicated in the genesis of AD, the formation
of amyloid plaques, and Aβ production, among other roles. Particularly, the dysregulation
of inflammatory mediators and astrogliosis are implicated in the development of chronic
inflammation and immunosenescence processes, as well as in cognitive decline and the
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progression of neurodegenerative diseases [45]. In agreement with this, in the current
study, Gfap gene expression was increased in female mice under CMS and subsequently
reduced after RL-118 treatment.
Recent studies have indicated that prolonged OS may limit autophagy flux [18]. In
addition, altered cellular loss of proteostasis is one of the nine hallmarks of aging postulated
by López-Otín et al. [46]. In accordance with previous reports, we found that GC-excess
attenuation by RL-118 promoted autophagy activation in the SAMP8 mice [23], while
CMS treatment induced autophagy deterioration [12]. In accordance, we report here that
autophagy flux was decreased in female mice under CMS, but RL-118-treated animals
showed higher protein levels of Beclin1, an increased LC3BI/II ratio, and lower protein
levels of p-TORC1 Ser151 in comparison to CMS control group, indicating the recovery of
autophagy in mice treated with RL-118 and under CMS.
11β-HSD1 inhibition has been studied in association with a number of disorders, one
of which is AD. It has been associated with reduced Aβ neurotoxicity and tau hyperphos-
phorylation [47,48], both of which are hallmarks of AD. The amyloid precursor protein
(APP) can be processed through two mechanisms: non-amyloidogenic and amyloidogenic
pathways. Adam10 is a marker of the former, and Bace1 is a marker of the latter [48,49]. In
this study, Adam10 gene expression was diminished and Bace1 was increased after CMS.
Importantly, the opposite was observed in RL-118 treated groups and the reported reduc-
tion in the formation of Aβ concurred with the Aβ-precursor gene expression shown here.
Moreover, gene expression for the Aβ-degrading enzyme Neprilisin12 was increased after
11β-HSD1-inhibitor treatment, but reduced after CMS.
As mentioned, prolonged exposure to GCs in the brain induces several changes.
Multiple studies state that repeated exposure to stressful conditions induces the structural
remodeling of neurons with synaptic loss as well as alterations in glial functions, which are
frequently maladaptive [8]. In agreement with this, our results demonstrate a reduction
in p-CREB/CREB protein levels after CMS exposure, but not in Creb gene expression.
Conversely, RL-118 treatment increased Creb gene expression, although it was not able to
prevent the deleterious effect of CMS [50]. In a similar way, 11β–HSD1 inhibition increased
synaptic plasticity markers, like PSD95 and synaptophysin. Thus, RL-118 treatment could
prevent the loss of those neuroplasticity markers, particularly synaptophysin [51].
The effects of GCs on cognition have been widely studied, showing that acute stress
improves cognitive abilities, while chronic stress worsens memory and learning processes
and accelerates brain aging [2,4,48]. In fact, GC levels variation has been found to correlate
with the severity of cognitive impairments [48]. In accordance with Puigoriol-Illamola
et al. [12,15], the mice under RL-118 treatment clearly showed improved recognition
memory when compared with the control mice. However, the injurious effects caused by
CMS were only detected during the evaluation of long-term recognition memory. Slight
changes were also observed in spatial memory, where 11β-HSD1 inhibition was observed
to improve the performance of mice, although a statistical difference was not detected.
However, RL-118 induced improved learning abilities in the CMS group, as the learning
curve slope was higher for the treated groups, indicating a putative role for RL-118 as a
neuroprotectant or cognition-enhancer.
It should be noted that one of the limitations of this study was that CMS was applied to
a strain of senescent mice with high basal levels of stress, inflammation, and OS, as reported
in Puigoriol et al., 2020 [12]. Therefore, it is possible that the CMS treatment did not worsen
cognitive abilities or certain stress markers due to the specific aging characteristics of
the SAMP8 mice. In fact, the beneficial effects obtained by the inhibition of 11β-HSD1
by RL-118 in the mice under CMS emphasize the importance of controlling GC levels to
mitigate the harmful effects of aging and stressful lifestyles.
This study demonstrates the target engagement between RL-118 and the 11β-HSD1
enzyme. Therefore, we can attribute the beneficial effects observed in the SAMP8 mice
treated with RL-118 to 11β-HSD1 inhibition. 11β-HSD1 inhibition by RL-118 was found
to improve most of the detrimental effects of CMS—including the enhancement of cogni-
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tive decline and antioxidant mechanisms—as well as improving synaptic plasticity and
autophagy markers. Additionally, the RL-118 treatment modulated epigenetic markers
and reduced inflammatory signaling and Aβ formation and accumulation (Figure 9).
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4. aterials and ethods
4.1. Cloning
The human E2-Crimson HSD11B1 gene (variant 1) was synthesized by GenScript
in vector pUC57. The DNA sequence for E2-Crimson was sourced from Clontech. The
gene for the fluorescent-HSD11B1 was ligated into vector pcDNA3.1 (Invitrogen) using
restriction sites NheI (N-terminus) and NotI (C-terminus) (Figure S1).
4.2. Transient Expression of the Fluorescent Target Protein
HEK293 cells were passaged in poly-D-Lysine treated plates and incubated overnight
in OPTI-MEM medium (Lonza) at 37 ◦C, 5% CO2. The cells were transiently transfected
the following day with pcDNA3.1-E1-Crimson-huHSD11B1 DNA using Lipofectamine
2000 (Invitrogen) in OPTI-MEM medium via standard transfection protocol. The trans-
fected cells were maintained at 37 ◦C, 5% CO2 for 24 h post-transfection before the TAPS
assay was performed. Transfection of the cells and compound screening were performed
in a 6-well plate format.
4.3. TAPS Assay
4.3.1. Compound Incubation
The RL-118 drug was diluted to a concentration of 20 µM (DMSO < 1%) in a tissue
culture medium (DMEM with 10% FBS, 1% L-Glutamine, 1% penicillin-streptomycin, (Life
Technologies, Carlsbad, CA, USA)), then incubated with transfected cells for three hours
at 37 ◦C, 5% CO2. A 20 µM compound concentration was selected as an appropriate
concentration for assay development and screening. Follo ing incubation, the cells were
detached from the plate by gentle pipetting and centrifuged for 5 min at 1000 rpm. The
culture medium was removed by pipetting and the cell pellet was re-suspended in FACS
buffer (PBS + 2% FBS) to wash off unbound compounds. The cells were centrifuged as
above, and the wash buffer was removed. The cells were then resuspended in FACS buffer
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and transferred to 5 mL FACS tubes. The tubes were wrapped in foil and placed on ice
until sorting.
4.3.2. FACS Sorting
Cells were sorted using a BD FACS Aria II system fitted with a 100 µm nozzle. Data
were acquired and processed using BD FACS Diva software version 8.0.1. Cell fluorescence
was detected using a 640 nm laser for E2-Crimson excitation. The filter used was 670/14 nm,
detecting fluorescence emission of E2-Crimson in the 663–677 nm range. Cells were sorted
and collected into four cell populations defined by fluorescence intensity. Forward- (FSC)
and side-scatter (SSC) gating was used to exclude dead cells and only live cells were
collected. Cells were collected in 5 mL FACS tubes containing 1 mL of DMEM with
10% FBS, 1% L-Glutamine, and 1% penicillin-streptomycin. Each population of cells was
centrifuged at 1000 rpm for 5 min. The medium was removed, and the cell pellet was
resuspended in 20 mM of HEPES, pH 7.0. The suspension was briefly sonicated to lyse
the cells before centrifugation, as before, to pellet cell debris. The lysate (supernatant) was
transferred to LC-MS vials and stored at −20◦C prior to MS analysis.
4.3.3. Mass Spectrometry Detection of the Compounds in Cell Lysates
The chromatographic and mass spectrometer used was the SCIEX Triple Quad
5500+ LC-MS/MS System- QTRAP (Triple QuadTM, Macclesfield, UK). A 10 µL injec-
tion of the cell lysate was loaded directly onto an HSST3 (150 mm × 2.1 mm, Thermo
Fisher Scientific, Waltham, MA, USA) column at a high flow rate, causing the proteinaceous
material to flow to waste. A series of valve switches led to the elution of the extracted
sample from the column directly onto the analytical column. Solvent A was water with
0.1% formic acid and solvent B was methanol with 0.1% formic acid. Automated tune
settings were used to achieve the maximum ion signal for the analyte for initial validation
experiments, optimizing tube lens voltage, parent-to-product transitions, and collision
energy for transition. Peaks detected in this initial scan were then identified by molecular
weight and checked versus their mass-charge ratio. Data were acquired and processed
using Sciex OS-MQ software (Macclesfield, UK).
4.4. Animals
Four-month-old female SAMP8 mice (n = 48) were used to carry out behavioral, cogni-
tive, and molecular analyses. We divided these animals into four groups: SAMP8 Control
(Control, n = 12), SAMP8 treated with RL-118 (11β-HSD1i, n = 12), SAMP8 under CMS
(CMS, n = 12), and SAMP8 treated with RL-118 under CMS (SAMP8 11β-HSD1i + CMS,
n = 12). Animals had free access to food and water and were kept under standard tempera-
ture conditions (22 ± 2 ◦C) and 12 h:12 h light–dark cycles (300 lux/0 lux). RL-118 was
administered at 21 mg/kg/day by oral gavage for 4 weeks. The dose administered was in
accordance with previous works [15,22,23], which demonstrated the efficacy of 21 mg/kg
of RL-118 for 4 weeks in mice. The chronic stressful stimuli consisted of several different
stressful stimuli applied to the corresponding animals daily for 4 weeks and was called
chronic mild stress (CMS) treatment.
Studies and procedures involving mice brain dissection and subcellular fraction-
ation were performed following standard ethical guidelines (European Communities
Council Directive 86/609/EEC) and were approved by the Institutional Animal Care
and Use Committee of the University of Barcelona (670/14/8102) and by Generalitat de
Catalunya (10291).
4.5. Chronic Mild Stress Treatment
The CMS procedure used in the present study has been previously validated in
SAMR1 and SAMP8 mice [12]. For 4 weeks, mice were exposed daily to various randomly
scheduled, low-intensity environmental stressors. The number and the type of stressful
events executed changed every day, as well as the sequence of the stressors, to guarantee
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the degree of unpredictability [12]. Stressful stimuli included 2 h of physical restraint,
24 h of sawdust removal, 24 h of food deprivation, 24 h of water deprivation, 24 h of wet
bedding, 1 min of tail nipping at 1 cm from the tip of the tail, and overnight illumination.
4.6. Behavioral and Cognitive Tests
4.6.1. Novel Object Recognition Test (NORT)
The Novel Object Recognition Test (NORT) protocol employed was as described in
Puigoriol-Illamola et al. [15]. In brief, mice were placed in a 90◦, two-arms, 25-cm-long,
20-cm-high, 5-cm-wide black maze. Before performing the test, the mice were individually
habituated to the apparatus for 10 min for 3 days. On day 4, the animals were submitted
to a 10-min acquisition trial (first trial), during which they were placed in the maze in the
presence of two identical, novel objects at the end of each arm. After a delay (2 h and
24 h), the animal was exposed to two objects: one old object and one novel object. The time
that mice explored the novel object (TN) and the time that mice explored the old object
(TO) were measured. A discrimination index (DI) was defined as (TN − TO)/(TN + TO).
To avoid object preference biases, objects were counterbalanced. The maze, the surface,
and the objects were cleaned with 70% ethanol between the animals’ trials to eliminate
olfactory cues.
4.6.2. Morris Water Maze (MWM)
This test evaluates both learning and spatial memory [52,53]. An open, circular
pool (100 cm in diameter, 50 cm in height) filled with water was used. The water was
painted white with latex to make it opaque, and its temperature was 22 ± 1 ◦C. Two main
perpendicular axes were established (north–south and east–west), thus configuring four
equal quadrants (NE, NW, SE, and SW). Four visual clues (N, S, E, W) were placed on
the walls of the tank so that the animal could orientate and fulfill the objective. The test
consists of training a mouse to find a submerged platform (learning phase) and assesses
whether the animal has learned, so that it could remember the platform’s location after
its removal (test). The training lasts five consecutive days and every day five trials are
performed—using different starting points (NE, E, SE, S, and SW)—with the aim that the
animal recognizes the visual clues and learns how to locate the platform, avoiding learning
a static path. For each trial, the mouse was placed gently into the water, facing the wall of
the pool, and allowed to swim for 60 s. There was no resting time between trials. If the
animal was not able to locate the platform, the investigator guided it to the platform and
allowed it to rest and orientate for 30 s. The platform was placed approximately in the
middle of one of the quadrants, 1.5 cm below the water level. Above the pool, there was a
camera that recorded the animals’ swimming paths, and the data were analyzed with the
statistical program SMART® ver.3.0 (Panlab, Barcelona, Spain). During the learning phase,
a learning curve was drawn, representing the latency to find the platform on each training
day. On the test day, the platform was removed, and more parameters were measured,
such as the target crossings and the distance swum to reach the platform zone.
4.7. Brain Processing
Three days after the behavioral and cognitive tests, 12 animals per group were eutha-
nized for protein extraction and RNA and DNA isolation. The brains were immediately
removed from the skull and the hippocampi were isolated, frozen on powdered dry ice,
and maintained at −80 ◦C until the procedures.
4.8. Western Blotting
Tissue samples were homogenized in lysis buffer (Tris HCl pH 7.4 50 mM, NaCl
150 mM, EDTA 5 mM, and 1 X-Triton X-100) containing phosphatase and protease inhibitors
(Cocktail II, Sigma-Aldrich, St. Louis, MI, USA) to obtain total protein homogenates. For
subcellular fractionation, 150 µL of buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM
EDTA pH 8, 0.1 mM EGTA pH 8, 1 mM DTT, 1 mM PMSF, protease inhibitors) were
Pharmaceuticals 2021, 14, 1040 16 of 19
added to each sample and incubated on ice for 15 min. After this time, the samples were
homogenized with a tissue homogenizer, and 12.5 µL of Igepal 1% was added and mixed
for 15 s. Following 30 s of full-speed centrifugation at 4 ◦C, supernatants were collected
(cytoplasmic fraction); 80 µL of buffer C (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA
pH 8, 0.1 mM EGTA pH 8, 20% Glycerol 1 mM DTT, 1 mM PMSF, protease inhibitors)
were added to each pellet and incubated under agitation at 4 ◦C for 15 min. Subsequently,
samples were centrifuged for 10 min at full speed at 4 ◦C. Supernatants were collected
(nuclear fraction) and 40 µL of buffer A + HCl (buffer A with 0.2 N HCl) were added to the
pellet. After a 30 min incubation on ice, samples were centrifuged, again at full speed, at
4 ◦C for 10 min and the supernatants were collected (the histone fraction). Aliquots of 15 µg
of hippocampal protein extraction per sample were used. Protein samples were separated
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (8–14%) and
transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore). Afterward,
the membranes were blocked in 5% non-fat milk in Tris-buffered saline (TBS) solution
containing 0.1% Tween 20 TBS (TBS-T) for 1 h at room temperature, followed by overnight
incubation at 4 ◦C with the primary antibodies listed in (Table S1). Then, the membranes
were washed and incubated with the secondary antibodies listed in (Table S1) for 1 h at
room temperature. Immunoreactive proteins were viewed with the chemiluminescence-
based ChemiLucentTM detection kit, following the manufacturer’s protocol (ECL Kit,
Millipore), and digital images were acquired using the ChemiDoc XRS + System (BioRad).
Semi-quantitative analyses were done using ImageLab software (BioRad) and results were
expressed in Arbitrary Units (AU), considering control protein levels as 100%. Protein
loading was routinely monitored by immunodetection of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), β-tubulin, or TATA-Binding protein (TBP).
4.9. RNA Extraction and Gene Expression Determination by q-PCR
Total RNA isolation was carried out using TRIsureTM reagent according to the man-
ufacturer’s instructions (Bioline Reagent, UK). The yield, purity, and quality of the RNA
were determined spectrophotometrically with a NanoDrop™ ND-1000 (Thermo Scientific)
apparatus and an Agilent 2100B Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
RNAs with 260/280 ratios and RIN higher than 1.9 and 7.5, respectively, were selected. A
reverse transcription-polymerase chain reaction (RT-PCR) was performed as follows: 2 µg
of messenger RNA (mRNA) was reverse-transcribed using the High-Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, Waltham, MA, USA). Real-time quantitative
PCR (qPCR) was used to quantify mRNA expressions of oxidative stress and inflammatory
genes listed in (Table S2). SYBR® Green real-time PCR was performed in a Step One Plus
Detection System (Applied-Biosystems, Waltham, MA, USA) employing SYBR® Green PCR
Master Mix (Applied-Biosystems, Waltham, MA, USA). Each reaction mixture contained
6.75 µL of complementary DNA (cDNA) (of which concentration was 2 µg), 0.75 µL of each
primer (of which concentration was 100 nM), and 6.75 µL of SYBR® Green PCR Master
Mix (2×).
Data were analyzed utilizing the comparative cycle threshold (Ct) method (∆∆Ct),
where the housekeeping gene level was used to normalize differences in sample loading
and preparation. The normalization of expression levels was performed with β-actin for
SYBR® Green-based real-time PCR results. Each sample was analyzed in duplicate, and the
results represent the n-fold difference of the transcript levels among the different groups.
4.10. Global DNA Methylation and Hydroxymethylation Determination
The isolation of genomic DNA was conducted using the FitAmpTM Blood and Cul-
tured Cell DNA Extraction Kit (EpiGentek, Farmingdale, NY, USA) according to the
manufacturer’s instructions. Following this, the Methylflash Methylated DNA Quantifi-
cation Kit (Epigentek, Farmingdale, NY, USA) and the MethylFlash HydroxyMethylated
DNA Quantification Kit were used in order to detect methylated and hydroxymethylated
DNA. In brief, these kits are based on the specific antibody detection of 5-mC and 5-hmC
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residues, which trigger an ELISA-like reaction that allows colorimetric quantification of
global DNA methylation and 5-hydroxymethylation at 450 nm. Both kits were used fol-
lowing the manufacturer’s instructions, including internal standards for methylated and
hydroxymethylated DNA.
4.11. Oxidative Stress Determination
Hydrogen peroxide was measured in hippocampus protein homogenates as an in-
dicator of oxidative stress and was quantified using the Hydrogen Peroxide Assay Kit
(Sigma-Aldrich, St. Louis, MI, USA) according to the manufacturer’s instructions. In
brief, the kit is based on detecting a red fluorescent product (λex = 540/λem = 590 nm)
generated after a reaction with hydrogen peroxide and can be analyzed by a fluorescent
microplate reader.
4.12. Data Analysis
The data analysis was conducted using GraphPad Prism ver. 7 statistical software.
Data are expressed as the mean ± standard error of the mean (SEM) of at least 6 samples
per group and 3 different experiments for the TAPS assay. CMS and drug treatment
effects were assessed by the Two-Way ANOVA analysis of variance, followed by a Tukey
post-hoc analysis or a two-tail Student’s t-test where necessary. Statistical significance
was considered when p-values were <0.05. The main effects and significant interaction
are shown in each graph. The statistical outliers were determined with Grubbs’ test and
subsequently removed from the analysis.
5. Conclusions
In conclusion, 11β-HSD1 inhibition through RL-118 treatment ameliorated the detri-
mental effects induced by CMS, including epigenetic and cognitive disturbances. This
indicates that GC-excess attenuation has potential as a therapeutic strategy for age-related
cognitive decline and AD.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/ph14101040/s1, Figure S1: HSD11B1 Protein sequence, HSD11B1 DNA sequence, and Fusion
Protein design; Table S1: Antibodies used in Western blot studies; Table S2: Primers and probes used
in qPCR studies.
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